2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Immunology, Autoimmune Disorders, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

1218 A four-variable clinical scoring system for differentiating idiopathic multicentric castleman disease from IgG4-related disease

Yu-han Gao, PhD, Yifei Wang, MD2, Linyi Peng, MD3, Jian Li, MD4, Wen Zhang, MD5, Lu Zhang, M.D.6
1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background

Idiopathic multicentric Castleman disease (iMCD) is characterized by systemic lymphadenopathy and frequently presents with elevated serum IgG4 levels within the context of polyclonal hypergammaglobulinemia. Differentiating iMCD from IgG4-related disease (IgG4-RD) poses a significant clinical challenge, as IgG4-RD also commonly involves lymph nodes and typically exhibits Castleman disease-like clinicopathological changes. Given that these overlapping serological features are predominantly observed in the iMCD-NOS subtype rather than the TAFRO variant, this study aims to systematically compare the immunoglobulin distribution patterns and inflammatory profiles between iMCD-NOS and IgG4-RD, and subsequently develop and validate a diagnostic nomogram to facilitate clinical differentiation.

Methods

This study included patients with IgG4-RD and iMCD diagnosed at Peking Union Medical College Hospital (PUMCH) between 2012 and 2025 with complete baseline data. For the iMCD group, patients were required to meet the 2017 Castleman Disease Collaborative Network (CDCN) diagnostic criteria and specifically belong to the iMCD-NOS subtype. IgG4-RD patients were selected from the prospective PUMCH IgG4-RD cohort (ClinicalTrials.gov: NCT01670695), fulfilling the 2019 ACR/EULAR classification criteria and/or the 2020 revised comprehensive diagnostic criteria, alongside lymph-node involvement (short-axis diameter ≥1 cm in ≥1 region). Demographic and laboratory variables were extracted. Feature selection was performed integrating Random Forest, Boruta, and LASSO regression. A predictive nomogram was subsequently developed to predict iMCD from IgG4-RD. Next, continuous variables were dichotomized using optimal cut-off values determined by the Youden index, and integer weights derived from multivariable logistic regression coefficients were assigned to construct a simplified diagnostic stratification system. Model discrimination and calibration were assessed using AUC, sensitivity, specificity, and mean absolute error (MAE). Robustness was confirmed through 1,000 bootstrap resamples.

Results

A total of 124 patients with iMCD and 178 patients with IgG4-RD were enrolled. Compared to the IgG4-RD group, iMCD patients exhibited significantly higher levels of total IgG, IgA, and IgM (all P < 0.001). Analysis of IgG subclasses revealed a pan-clonal elevation in iMCD patients. Levels of IgG1 (25785 vs 9190 mg/L), IgG2 (7785 vs 4830 mg/L), and IgG3 (925 vs 540 mg/L) were all significantly higher than in the IgG4-RD group (all P < 0.001), whereas IgG4 significantly lower (3239 vs 12050 mg/L, P < 0.001), yielding a substantially distinct IgG1/IgG4 ratio (P < 0.001). Furthermore, iMCD patients exhibited a more pronounced systemic inflammatory and consumptive state, with significantly lower hemoglobin (94 vs 137 g/L) and albumin (31 vs 42 g/L), and elevated C-reactive protein (79.81 vs 1.60 mg/L) and erythrocyte sedimentation rate (100 vs 23 mm/h) (all P < 0.001).  A diagnostic nomogram incorporating IgG1, the IgG1/IgG4 ratio, albumin, and CRP was developed to differentiate iMCD from IgG4-RD. The model demonstrated excellent discrimination, yielding an AUC of 0.972 (sensitivity: 93.6%, specificity: 93.3%), with internal validation confirming minimal overfitting (optimism-corrected AUC = 0.966) and a highly accurate calibration curve (MAE = 0.031). To facilitate clinical application, the nomogram was translated into an 8-point clinical scoring system: albumin < 35 g/L (1 point), CRP > 12 mg/L (2 points), IgG1 > 15500 mg/L (2 points), and IgG1/IgG4 ratio > 2.25 (3 points). This simplified system maintained an outstanding AUC of 0.978 and successfully stratified patients into three diagnostic certainty categories for iMCD: "Not likely" (0-2 points; 1.4% probability), "Possible" (3-4 points; 25.7% probability), and "Probable" (5-8 points; 95.0% probability).

Conclusions

iMCD is characterized by severe systemic inflammation and pan-clonal IgG elevation driven primarily by IgG1, contrasting with the selective IgG4 increase in IgG4-RD. A novel 4-variable clinical scoring system based on albumin, CRP, IgG1, and the IgG1/IgG4 ratio provides a highly accurate and robust tool to differentiate iMCD-NOS from IgG4-RD in clinical practice.

Yu-han Gao, PhD: No relevant conflicts of interest to declare.